What changed
Adjusted diluted EPS of $3.34 topped the $3.28 consensus by $0.06, or 2.0%. Revenue came in at $4,428M, up 8.0% YoY (8.6% constant currency), with Commercial Solutions +6.9% and R&D Solutions +8.7%. Management raised FY2026 guidance to adjusted EPS of $12.90-$13.00 and revenue of $17.4B-$17.5B. The beat was driven by broad demand strength and margin expansion, with R&D net new bookings of $3.2B up 15% YoY marking the strongest clinical quarterly bookings since 2022.
Why it matters
Adjusted diluted EPS of $3.34 topped the $3.28 consensus by $0.06, or 2.0%. Revenue came in at $4,428M, up 8.0% YoY (8.6% constant currency), with Commercial Solutions +6.9% and R&D Solutions +8.7%. M